Sign up Australia
Proactive Investors - Run By Investors For Investors

Actinogen Medical raises $10M for Alzheimer’s drug trial

Actinogen Medical raises $10M for Alzheimer’s drug trial

Sydney based Actinogen Medical (ASX:ACW) has raised $10.0 million to further a trial of its very promising drug to fight Alzheimer’s disease.

The funds were raised in a placement which saw heavy investor demand at an issue price of $0.095 per share.

The Phase 2 trial of its drug Xanamem™ is planned to start in 2016 and for it to run in Australia/New Zealand, the USA and the UK.

Xanamem blocks cortisol production which is a key plank in the fight against Alzheimer's disease to stop the disease at an early stage.

Excess cortisol is associated with memory loss and amyloid plaques, hallmarks of Alzheimer’s disease.

The capital raising will also be used to support the IND filing with US FDA.

A share purchase plan will also raise an additional $1 million.

Alzheimer’s disease is the most common form of dementia and has a debilitating effect on patients and families. At present, there is no viable cure for sufferers.

Alzheimer’s is now the second leading cause of death in Australia behind ischaemic heart disease.

Estimates by the American Alzheimer’s Association indicate that the direct healthcare cost of the disease was $US250 billion in 2013.

This is projected to rise to over $US1 trillion by 2050, outstripping the cost of treating all other diseases.

 

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.





Register here to be notified of future ACW Company articles
View full ACW profile View Profile

Actinogen Medical Ltd Timeline

Newswire
December 30 2016

Related Articles

shutterstock_212432119.jpg
August 01 2017
VolitionRx will contribute just $3mln towards the trial as opposed to a usual $30-$40mln for something on this scale.
eye-766166_1280_583251a48f148.jpg
November 21 2016
The flagship product, CardioCel, is a bio-engineered tissue scaffold used in the heart valve repair market.
blood_56ceb82789b61.jpg
December 15 2016
The company's nominated adviser said a partnership deal should be signed by the end of 2016

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use